Stock data
| Market cap. | €140.8m |
| Last close | €3.60 |
| High / Low (52 weeks) | €5.0 / €2.1 |
| Stock market listing | SP |
| Forecast net cash (€m) | 11.6 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceuticals & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 31.9 | 29.0 | 36.9 |
| Relative * | 30.3 | 24.6 | 47.5 |
* % Relative to local index
Other companies in sector Show
Company news
Investment summary
Oryzon’s expertise lies in developing small molecule inhibitors for epigenetic targets. Oryzon’s lead CNS product vafidemstat (ORY-2001), a dual LSD1/MAOB inhibitor, targets Alzheimer’s disease (Phase IIa initiated), multiple sclerosis (Phase IIa initiated) and other neurodegenerative indications. Results from both trials are expected in 2019. Oryzon has also initiated a Phase IIa trial studying vafidemstat (ORY-2001) in aggressiveness. The lead oncology product iadademstat (ORY-1001) is a specific LSD1 inhibitor with positive data from the Phase I/IIa in acute myeloid leukaemia (AML) announced in December 2016. A Phase IIa trial in AML and Phase IIa trial in SCLC have recently initiated.
Last updated on 01/02/2019
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 5.0 | (3.7) | (4.7) | (17.02) | N/A | N/A |
| 2017A | 4.3 | (3.5) | (4.6) | (14.29) | N/A | N/A |
| 2018E | 7.0 | (4.7) | (5.6) | (9.23) | N/A | N/A |
| 2019E | 6.3 | (6.4) | (7.3) | (18.56) | N/A | N/A |
Last updated on 17/12/2018
Latest research
Ramping up R&D activity; catalysts in 2019
Update | Pharmaceuticals & healthcare | 09/11/2018
Awaiting for eventful 2019
Outlook | Pharmaceuticals & healthcare | 18/07/2018
Phase IIa trial in Alzheimer's disease initiated
Update | Pharmaceuticals & healthcare | 22/05/2018
Multiple data readouts in 2019 within cash reach
Update | Pharmaceuticals & healthcare | 08/03/2018
New data support holistic effects of ORY-2001
Update | Pharmaceuticals & healthcare | 14/12/2017
ORY-1001 rights back to Oryzon
Update | Pharmaceuticals & healthcare | 22/08/2017
Roche returns rights on ORY-1001
Flash note | Pharmaceuticals & healthcare | 21/07/2017
ORY-2001 and ORY-3001 next in focus
Update | Pharmaceuticals & healthcare | 22/05/2017
Maturing epigenetics portfolio
Outlook | Pharmaceuticals & healthcare | 02/05/2017
New data further back MS indication
Update | Pharmaceuticals & healthcare | 13/03/2017
Expanding clinical R&D pipeline
Update | Pharmaceuticals & healthcare | 09/12/2016
First look at ORY-1001 Phase I/IIa data
Update | Pharmaceuticals & healthcare | 16/11/2016
Latest video
Industry outlook
Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.
Last updated on 01/02/2019
Key management
| Carlos Buesa, CEO |
Company address
| Sant Ferran 74 Cornellà de Llobregat Barcelona 08940 United Kingdom View website |